Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain

Mohammad Ezzati, Bruce R. Carr

Research output: Contribution to journalReview article

20 Scopus citations

Abstract

Suppression of estrogen production and reduction of menstrual blood flow are the mainstays of medical treatment of endometriosis-related pain and have been traditionally achieved by methods such as combined hormonal contraception, progestins and GnRH analogs, all with comparable efficacies, though different side-effect profiles. Elagolix is the frontrunner among an emerging class of GnRH antagonists, which unlike their peptide predecessors has a nonpeptide structure resulting in its oral bioavailability. Phase I and II clinical trials have demonstrated safety of elagolix and its efficacy in partial and reversible suppression of ovarian estrogen production resulting in improvements in endometriosis-related pain. Phase III clinical trials are currently underway and elagolix may become a valuable addition to the armamentarium of pharmacological agents to treat endometriosis-related pain.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalWomen's Health
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2015

Keywords

  • Bone mineral density
  • GnRH antagonists
  • elagolix
  • endometriosis
  • medical treatment

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain'. Together they form a unique fingerprint.

  • Cite this